We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





AACC Disruptive Technology Award Finalists Tackle Cancer, Women's Health, and STDs

By LabMedica International staff writers
Posted on 27 Jul 2022

Biological Dynamics (San Diego, CA, USA), Nanopath (Cambridge, MA, USA) and Visby Medical (San Jose, CA, USA) have been selected as the finalists for AACC’s 2022 Disruptive Technology Award. More...

The three finalists presented early-stage cancer detection technology, point-of-care molecular diagnostics using optical detection, and a rapid sexually transmitted disease assay during the 2022 AACC Annual Scientific Meeting and Clinical Lab Expo. AACC’s Disruptive Technology Award recognizes innovative testing and disruptive technology solutions that improve patient care through diagnostic performance or access to high quality testing.

Biological Dynamics presented its Verita Isolation Platform, which will become the basis of an annual screening blood test for multiple cancers, according to the company. The platform uses technology for isolating nanoparticles and macromolecules from whole blood, plasma, serum, urine, and saliva. The company recently received an FDA Breakthrough Device Designation for its first liquid biopsy assay that uses the platform for the early detection of pancreatic ductal adenocarcinoma using exosomal proteins.

Nanopath presented its Nanopath Platform, a solid-state biosensing platform with ultrasensitive optical detection. This feature eliminates the need for nucleic acid amplification and provides clinically actionable genetic information in less than 15 minutes. According to the company, the platform should be a “go-to” system for routine women’s health screening at the point of care because it enables high-complexity tests and allows physicians and clinics to get testing revenue. To date, the company has generated preliminary data in two clinical indications: human papillomavirus genotyping and urinary tract infection characterization.

Visby Medical PRC Point-of-Care Tests run on an instrument and cartridge-free, single-use PCR platform that fits in the palm of the hand and delivers accurate results about causes of serious infections in under 30 minutes. The test would eliminate the need to send samples to remote central labs for processing and has been shown to detect DNA from chlamydia, gonorrhea, and trichomoniasis. The platform could benefit patients in remote areas without access to high complexity labs.

Related Links:
Biological Dynamics 
Nanopath 
Visby Medical 


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining System
RAL DIFF-QUIK
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.